This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| inter partes review | |
|---|---|
| Name | Inter partes review |
| Court | United States Patent and Trademark Office |
| Established | 2012 |
| Statute | America Invents Act |
| Jurisdiction | United States |
| Related | Patent Trial and Appeal Board, patent |
inter partes review
Inter partes review is an administrative procedure created by the America Invents Act that permits third parties to challenge the validity of issued patents before the Patent Trial and Appeal Board of the United States Patent and Trademark Office. It provides a faster, adjudicative alternative to district court litigation, involving specialized agency judges and technical records, and has intersected with landmark cases from the Supreme Court of the United States and debates involving firms such as Apple Inc., Samsung Electronics, and Google LLC.
Inter partes review was implemented by the America Invents Act as a post-grant review mechanism to address questions of novelty and non-obviousness under §§ 102 and 103, replacing earlier procedures like inter partes reexamination. The procedure is administered by the Patent Trial and Appeal Board, an adjudicatory unit within the United States Patent and Trademark Office, and has been shaped by jurisprudence from the Supreme Court of the United States, decisions from the Federal Circuit, and policy input from the United States Department of Commerce.
A party petitions the Patent Trial and Appeal Board to institute review, typically presenting prior-art references such as patents from the United States Patent and Trademark Office, publications indexed in the United States Copyright Office records, or technical disclosures from companies like IBM, Intel Corporation, or Microsoft. The Director of the United States Patent and Trademark Office or delegated Board panels decide institution based on statutory thresholds, including whether there is a "reasonable likelihood" of prevailing, and issues an institution decision. If instituted, discovery is limited compared with civil actions in the United States District Courts, and the Board issues a final written decision within statutory timeframes, subject to administrative and judicial appeal to the United States Court of Appeals for the Federal Circuit. Parties may seek motions to amend claims, rely on expert testimony, and invoke rules from the Administrative Procedure Act in ancillary challenges.
Petitions commonly assert invalidity under prior art grounds tied to Section 102 and Section 103 of the patent statutes, relying on references like earlier patents held by Sony Corporation, General Electric, or publications linked to research from institutions such as Massachusetts Institute of Technology and Stanford University. The Board applies standards developed by the Federal Circuit and occasionally reviewed by the Supreme Court of the United States, including constructions from claim-construction doctrines and doctrines like obviousness-type double patenting. The substantive burden for institution requires a showing of a reasonable likelihood of success, while the final decision rests on a preponderance of the evidence standard.
Estoppel blocks petitioners from raising in later United States District Court litigation grounds that were or could have been raised in the Board proceeding, a rule that has produced litigation involving appellants such as Medtronic, Qualcomm, and Eli Lilly and Company. Board final decisions are appealable to the United States Court of Appeals for the Federal Circuit, and the Supreme Court of the United States has addressed scope questions in cases implicating estoppel and institutional authority. Collateral challenges may invoke constitutional claims against agency adjudication analogous to disputes involving the Federal Trade Commission or the Securities and Exchange Commission.
Since inception, tens of thousands of petitions have been filed, affecting portfolios held by major firms including Amazon.com, Cisco Systems, and Tesla, Inc., and altering valuation and enforcement strategies across industries from Pharmaceutical Research companies like Pfizer and Merck & Co. to semiconductor firms like TSMC. Academic centers such as Harvard University and University of California research have tracked institution rates, claim-cancellation percentages, and settlement patterns, while think tanks and agencies such as the Congressional Research Service have produced empirical analyses influencing policy debates in United States Congress hearings.
Critiques have come from litigants, law firms, and industry groups including the American Intellectual Property Law Association and major corporations like Apple Inc. and Samsung Electronics, arguing that the process can undermine patent certainty, favor repeat petitioners like specialized litigants labeled as patent assertion entities and raise constitutional issues about agency adjudication. Legal challenges reached the Supreme Court of the United States in landmark rulings that clarified aspects of administrative removal and the Director’s discretion, prompting statutory and regulatory responses from the United States Patent and Trademark Office and commentary from the United States Department of Justice.
Similar post-grant invalidation mechanisms exist in other jurisdictions, such as opposition proceedings before the European Patent Office and re-examination systems at the Japan Patent Office and Korean Intellectual Property Office, influencing multinational firms like Siemens and Huawei Technologies in cross-border portfolio strategies. Comparative scholarship from institutions like the World Intellectual Property Organization and legal academics at Yale Law School and Columbia Law School examines divergences in standards, appeal routes to national courts, and the balance between patent quality and innovation incentives across systems including the European Union and Canada.